Session I

Cancer Susceptibility

New approaches to new susceptibility gene discovery and practical aspects of testing for known susceptibility genes.

Speakers:

Charles R. Cantor, Ph.D.
Gigi Lozano, Ph.D.
Allan Balmain, Ph.D., FRSE
Brian Ward, Ph.D.

Cancer Detection

Both serum and cell-based assays for cancer detection will be discussed. Speakers will address assays for early cancer detection, detection of residual and recurrent disease and detection of disseminated metastatic cells.

Speakers:

Noel L.Warner, Ph.D.
Steve Seelig, M.D., Ph.D.
Gordon B. Mills, M.D., Ph.D.

Prediction and Prognosis

This session will address predictive and prognostic markers. Predictive markers reveal tumor or host characteristics that influence response to specific therapies. Prognostic markers are those that reveal intrinsic tumor characteristics that determine disease behavior.

Speakers:

John Sninsky, Ph.D.
David Eberhard, Ph.D.
Laura J. Esserman, M.D., M.B.A.
Suzanne Fuqua, Ph.D.

Presenters will discuss academic, industrial and U.S. efforts to collect, manage and interpret clinical and research information that arises during the course of translational research.

Speakers:

Mike Eisen, Ph.D.
Ken Buetow, Ph.D.
Barry Robson, Ph.D.

Session V

Therapeutic Targets (Identification and Validation)

This session will focus on approaches to identifying new therapeutic targets and the development of targeted therapies. These talks will cover practical, scientific and business aspects of target validation and therapy development.

Speakers:

Geoff Wahl, Ph.D.
Lans Taylor, Ph.D.
Brian Mullaney, M.D., Ph.D.
Don Small, M.D., Ph.D.